FDA reports rodent infestation at Louisville food distributor
LOUISVILLE, Ky. (FOX 56) — The Food and Drug Administration (FDA) advised people to avoid eating food from a Louisville company after learning the company had a rodent problem.
According to an announcement by the FDA, an active rodent infestation and droppings on multiple product containers were found during a May inspection at the Pan-African Food Distributors.
FDA reports rodent infestation at Louisville food distributor
Man agrees to Alford plea in connection with 2016 Lincoln County death
Kentucky artists perform tornado benefit concert in downtown Somerset
In response to the inspection, the state of Kentucky has ordered the company to cease operations since it lacked a required permit. Kentucky has also implemented a 'blanket quarantine of product.'
The FDA confirmed that the business will be prohibited from reopening until the infestation has been completely addressed. A recall on all Pan-African food products currently on the market was recommended by the FDA, and the company agreed to comply.
Read more of the latest Kentucky news
Customers are encouraged by the FDA to check their homes for all Pan-African food and throw away all related products.
For a full list of products distributed by Pan-African Food Distributors, click here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus hormone therapy versus hormone therapy alone, with positive trend in overall survival (OS)1 Pluvicto is already approved for metastatic castration-resistant prostate cancer (mCRPC) and now shows potential in patients in an earlier disease setting1,2 Novartis to present results at an upcoming medical meeting and, based on FDA feedback, will submit for regulatory review in the second half of the year Novartis is investigating a broad portfolio of RLTs in advanced cancers, including breast, colon, lung and pancreatic and is investing in multiple manufacturing facilities, with industry-leading infrastructure to accelerate delivery of RLTs to patients Basel, June 2, 2025 – Novartis today announced topline results from a pre-specified interim analysis of the Phase III PSMAddition trial. The trial met its primary endpoint with a statistically significant and clinically meaningful benefit in radiographic progression-free survival (rPFS) with a positive trend in overall survival (OS) in patients with prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer (mHSPC) treated with radioligand therapy (RLT), Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan), in combination with standard of care (SoC) versus SoC alone1. In PSMAddition, the SoC is a combination of androgen receptor pathway inhibitor (ARPI) therapy and androgen deprivation therapy (ADT)3. Almost all mHSPC patients ultimately progress to metastatic castration-resistant prostate cancer (mCRPC)4. There is a need for additional treatment options with novel mechanisms of action that further delay progression, prolong OS and improve disease control compared to the current SoC, while showing a favorable safety and tolerability profile. 'The progression from metastatic hormone-sensitive prostate cancer to castration-resistant disease remains a formidable challenge that can profoundly impact the survival of patients," said Shreeram Aradhye, M.D., President, Development and Chief Medical Officer at Novartis. "These results further strengthen our confidence in Pluvicto as a PSMA-targeted radioligand therapy. Following the recent FDA approval based on the PSMAfore trial in metastatic castration-resistant prostate cancer, these data suggest using it in an earlier disease setting could advance care and address a significant unmet need for hormone-sensitive prostate cancer patients." This is the third positive read-out for Pluvicto in a Phase III trial, following the VISION and PSMAfore studies5,6. Results from PSMAddition in mHSPC show potential for treatment in an earlier setting with Pluvicto, which was recently granted US Food and Drug Administration (FDA) approval for earlier use in mCRPC, based on results from PSMAfore1,2. Novartis is harnessing the innovation of world-class scientists, strategic partnerships and one of the industry's most competitive pipelines to explore the potential of new, targeted therapies and precision medicine platforms to address the greatest unmet needs in prostate cancer. Data will be presented at an upcoming medical meeting and, based on FDA feedback, will be submitted for regulatory review in the second half of the year. About PSMAddition studyPSMAddition (NCT04720157) is a Phase III, open-label, prospective, 1:1 randomized study comparing the efficacy and safety of Pluvicto in combination with SoC (ARPI + ADT) vs. SoC alone in adult patients with PSMA-positive mHSPC3. Patients randomized to the SoC alone arm are allowed to crossover to receive Pluvicto, upon confirmation of radiographic progression by blinded independent review committee (BIRC) and per the discretion of the treating physician3. The primary endpoint is rPFS, defined as the time to radiographic progression by PCWG3-modified RECIST V1.1 (as assessed by BIRC) or death3. The key secondary endpoint of OS is defined as time to death due to any cause3. About Pluvicto™ (INN: lutetium (177Lu) vipivotide tetraxetan)Pluvicto is an intravenous RLT that combines a targeting compound (a ligand) with a therapeutic radionuclide (a radioactive particle, in this case lutetium-177)5,7. After administration into the bloodstream, Pluvicto binds to PSMA-expressing target cells, including prostate cancer cells that express PSMA, a transmembrane protein5,7. Once bound, energy emissions from the radioisotope damage the target cells and nearby cells, disrupting their ability to replicate and/or triggering cell death7. Pluvicto is the only PSMA-targeted agent approved for PSMA-positive mCRPC and is the first targeted RLT to demonstrate a clinical benefit for patients with PSMA-positive mHSPC1. Novartis is investigating Pluvicto in earlier stages of disease, including oligometastatic prostate cancer (PSMA-DC, NCT05939414). Novartis and radioligand therapy (RLT)Novartis is reimagining cancer care with RLT for patients with advanced cancers. By harnessing the power of targeted radiation and applying it to advanced cancers, RLT is designed to deliver treatment directly to target cells, anywhere in the body8,9. Novartis is investigating a broad portfolio of RLTs, exploring new isotopes, ligands and combination therapies to look beyond gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and prostate cancer and into breast, colon, lung and pancreatic cancer. Novartis has established global expertise, with specialized supply chain and manufacturing capabilities across its network of RLT production sites. To support growing demand for RLTs, we have expanded production capabilities in Millburn (NJ), Zaragoza (Spain), Ivrea (Italy) and a state-of-the-art facility in Indianapolis (IN). In Carlsbad (CA), Novartis is establishing its third US-based RLT manufacturing site to support expanded use of RLTs, create resiliency in its manufacturing network and optimize the delivery of medicines to patients on the West Coast. DisclaimerThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as 'potential,' 'can,' 'will,' 'may,' 'could,' 'trend,' 'potentially,' 'upcoming,' 'progression,' 'progress,' 'investigating,' 'investing,' 'look beyond,' or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for Pluvicto, or regarding potential future revenues from Pluvicto. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Pluvicto will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that Pluvicto will be commercially successful in the future. In particular, our expectations regarding Pluvicto could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. References Data on file. Pluvicto [prescribing information]. Millburn, NJ: Advanced Accelerator Applications USA, Inc.; 2025. An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition). identifier: NCT04720157. Updated March 5, 2025. Accessed June 2, 2025. Oing C, Bristow RG. Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy. ESMO Open 2023l doi: 10.1016/ Sartor O, J. de Bono KN, Chi K, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. NEJM 2021; doi: 10.1056/NEJMoa2107322. Morris M, Castellano D, Herrmann K, et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. The Lancet 2024; doi: 10.1016/S0140-6736(24)01653-2. University of Chicago Medicine. Lutetium-177 PSMA Therapy for Prostate Cancer (Pluvicto). Accessed June 18, 2024. Jadvar H. Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment [published correction appears in AJR Am J Roentgenol. 2017 Oct;209(4):949. doi: 10.2214/AJR.17.18875]. AJR Am J Roentgenol. 2017;209(2):277-288. doi:10.2214/AJR.17.18264 Jurcic JG, Wong JYC, Knoc SJ, et al. Targeted radionuclide therapy. In: Tepper JE, Foote RE, Michalski JM, eds. Gunderson & Tepper's Clinical Radiation Oncology. 5th ed. Elsevier, Inc. 2021;71(3):209-249 # # # Novartis Media RelationsE-mail: Novartis Investor RelationsCentral investor relations line: +41 61 324 7944E-mail: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
an hour ago
- Business Insider
10 rich countries non-committal on Zimbabwe's $2.6b bridge financing appeal
Zimbabwe is yet to secure any firm pledges of financial support from the 10 countries it appealed to in its ongoing bid to settle long-standing debt arrears. Zimbabwe is actively seeking financial support from 10 nations to address its $21 billion debt burden. The country has been unable to access global financial markets since its default in 1999. Zimbabwe has requested $2.6 billion in bridge financing to address debts to international lenders. Zimbabwe is yet to secure any firm pledges of financial support from the 10 countries it appealed to in its ongoing bid to settle long-standing debt arrears. The southern African nation is burdened with a $21 billion debt, which has shut it out of global financial markets since it defaulted in 1999, according to Bloomberg. According to Finance Minister Mthuli Ncube, he had sent letters to Algeria, Brazil, China, France, Germany, Italy, Japan, South Africa, the United Arab Emirates, and the UK, requesting $2.6 billion in bridge financing to help settle debts owed to major multilateral lenders, including the World Bank, the European Investment Bank, and the African Development Bank. However, responses from the countries Zimbabwe approached for debt relief have been mixed. "Some of them are very warm, some of them not so warm. You will get a varied response,' he said. One of the major hurdles to securing the bridge financing is that seven of the countries he contacted, including China and Germany, are already creditors to Zimbabwe. Collective support needed Given the large amount of funding Zimbabwe is seeking, it's unlikely that a single nation will step in as a sponsor. Ncube stressed that it would require a collective effort of at least three countries. He also noted that Zimbabwe may explore other avenues to raise funds for debt repayment, including asset sales, though he did not offer specifics.
Business Upturn
3 hours ago
- Business Upturn
Stocks to watch on June 2: Vodafone Idea, Nykaa, Apollo Hospitals, Bharti Airtel, M&M, IndiGo, Astral, Sun TV, Indian steel, cement in focus on brokerage views
A host of stocks will be on investor radar today as top brokerages released fresh reports post Q4 earnings and sector updates. Vodafone Idea: underperform / neutral / buy Advertisement Macquarie has an Underperform call on Vodafone Idea with a target of ₹6.5. The brokerage flagged a soft Q4, subscriber erosion and higher interest burden. It sees challenges in further equity infusion by the government. JP Morgan is Neutral with a target of ₹8, noting broadly in-line Q4 results but capex below estimates. The company is pursuing a ₹20,000 crore equity fundraise. UBS remains Buy with a target of ₹12.10, though noting Q4 miss and market share losses. It will monitor fundraising, capex, and 5G rollout. Nykaa (FSN Ecom): hold / sell / neutral HSBC downgraded to Hold with a target of ₹200, flagging limited clarity on fashion business break-even. Citi maintained Sell with a target of ₹160, citing weak fashion segment margins despite broad-based BPC growth. Nomura remains Neutral with a target of ₹216, positive on BPC and awaiting better margin trends in fashion. Apollo Hospitals: neutral / overweight / buy Nomura has a Neutral call with a target of ₹6,856, noting in-line revenues but PAT 19% above estimates. Morgan Stanley is Overweight, trimming target to ₹8,058, bullish on patient-centric model and new bed additions. Citi reiterated Buy with a target of ₹8,260, positive on core healthcare margins and pharmacy growth. Bharti Airtel: buy Jefferies reiterated Buy with a raised target of ₹2,370 (CMP: ₹1,859.70). It sees 30%+ rerating potential on subscriber premiumisation, falling capex intensity, and robust revenue CAGR of 14-17%. Mahindra & Mahindra: buy UBS reiterated Buy with a target of ₹3,700, projecting 15-18% SUV volume growth, positive exports outlook, and upcoming EV launches. IndiGo (InterGlobe Aviation): buy Jefferies maintained Buy with a target of ₹6,300. It highlighted first-mover advantage at the Navi Mumbai International Airport and international expansion into Europe, Central Asia, and Southeast Asia. Astral: hold Jefferies has a Hold call with a target of ₹1,565 (CMP: ₹1,500.10), flagging rich valuations after a 17% rally, with current PE 25% above long-term average. It expects 14-19% earnings CAGR. Sun TV: hold CLSA reiterated Hold with a target of ₹655. FY25 revenue missed estimates due to 4% YoY ad revenue decline. IPL revenue fell 3% YoY. CLSA cut estimates but expects 9% earnings CAGR through FY28. Colgate-Palmolive: overweight JP Morgan reiterated Overweight on Colgate with a target of ₹2,750. It expects back-ended revenue growth in FY26, with margins holding steady. The brokerage is positive on Colgate's category development, premiumisation, innovation, and sees enhanced distribution execution as a key driver. Cement sector: positive Nomura highlighted significant price hikes in South India, up ₹19/bag MoM, driving pan-India average price gains of ₹12/bag QoQ in Q1FY26. The firm remains constructive on earnings outlook. Indian steel sector: mixed Morgan Stanley said Indian steel is still 15% more expensive than imported steel. Imports have declined recently but may rise again. A rally in Indian steel stocks is driven by strong local demand, with positive signals from China reducing steel supply. Indian economy: positive but cautious Morgan Stanley also issued an update on India's macro outlook, noting 7.4% GDP growth and 6.8% GVA, both above expectations. Industrial activity is robust but growth could moderate due to weak global demand and policy risks. Disclaimer: This article is for informational purposes only and does not constitute investment advice.
